Skip to Main Content

Paper Details

KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy.
Mod Pathol
15
2020
Author NameAffiliation
Somak RoyUniversity of Pittsburgh Medical Center
Nathan BaharyHillman Cancer Center, University of Pittsburgh Medical Center
  • 1 - 2

Datasets

Release 1.2